| 30/04/26 | 09:30:00 | 30 Apr 2026 | | Total Voting Rights |
| 29/04/26 | 11:00:00 | 29 Apr 2026 | | HUTCHMED Announces NDA Acceptance in China |
| 09/04/26 | 09:30:00 | 9 Apr 2026 | | 2025 Annual Report and Notice of AGM |
| 09/04/26 | 07:00:07 | 9 Apr 2026 | | Data to be Presented at AACR Annual Meeting 2026 |
| 23/03/26 | 07:00:13 | 23 Mar 2026 | | HUTCHMED Initiates Phase III Trial of HMPL-760 |
| 16/03/26 | 08:30:00 | 16 Mar 2026 | | Vesting of awards under Long Term Incentive Plan |
| 11/03/26 | 08:30:00 | 11 Mar 2026 | | Vesting of awards under Long Term Incentive Plan |
| 09/03/26 | 09:30:00 | 9 Mar 2026 | | Update on Licensed Oncology Product in China |
| 06/03/26 | 08:30:00 | 6 Mar 2026 | | Directorate change |
| 05/03/26 | 13:00:00 | 5 Mar 2026 | | Publication of Form 20-F |
| 05/03/26 | 11:00:01 | 5 Mar 2026 | | 2025 Full Year Results and Business Updates |
| 04/03/26 | 08:30:00 | 4 Mar 2026 | | HUTCHMED Initiates Global Trial of ATTC Candidate |
| 06/02/26 | 08:30:00 | 6 Feb 2026 | | HUTCHMED to Announce 2025 Final Results |
| 14/01/26 | 07:00:09 | 14 Jan 2026 | | Publication of Phase III Results in The Lancet |
| 07/01/26 | 07:00:07 | 7 Jan 2026 | | Positive Topline Results of Phase III Trial |
| 05/01/26 | 07:00:07 | 5 Jan 2026 | | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31/12/25 | 07:00:03 | 31 Dec 2025 | | Total Voting Rights |
| 30/12/25 | 10:00:00 | 30 Dec 2025 | | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29/12/25 | 08:30:00 | 29 Dec 2025 | | NDA Acceptance in China for Fanregratinib |
| 29/12/25 | 08:30:00 | 29 Dec 2025 | | Blocklisting Six Monthly Return |
| 17/12/25 | 07:00:10 | 17 Dec 2025 | | HUTCHMED Initiates Development of ATTC Candidate |
| 08/12/25 | 07:00:11 | 8 Dec 2025 | | Expanded NRDL Coverage + CIDL Inclusion in China |
| 28/11/25 | 08:30:01 | 28 Nov 2025 | | Total Voting Rights |
| 27/11/25 | 07:00:15 | 27 Nov 2025 | | HUTCHMED Highlights Data at ESMO and ASH |
| 05/11/25 | 07:00:12 | 5 Nov 2025 | | Enrollment Complete in SAFFRON Global Phase III |
| 03/11/25 | 07:00:12 | 3 Nov 2025 | | Updates from R&D Event |
| 23/10/25 | 07:00:10 | 23 Oct 2025 | | HUTCHMED Presents Data at AACR NCI EORTC |
| 21/10/25 | 09:30:00 | 21 Oct 2025 | | Vesting of awards under Long Term Incentive Plan |
| 14/10/25 | 09:30:00 | 14 Oct 2025 | | Appointment of Independent Non-executive Director |
| 13/10/25 | 07:05:14 | 13 Oct 2025 | | Data to be Presented at the 2025 ESMO Congress |
| 02/10/25 | 07:00:12 | 2 Oct 2025 | | HUTCHMED Highlights Data to be Presented at ESMO |
| 30/09/25 | 09:30:00 | 30 Sept 2025 | | Total Voting Rights |
| 12/09/25 | 07:00:18 | 12 Sept 2025 | | HUTCHMED to Present R&D Updates on October 31 2025 |
| 05/09/25 | 07:00:09 | 5 Sept 2025 | | HUTCHMED Highlights Data to be Presented at CSCO |
| 26/08/25 | 07:00:14 | 26 Aug 2025 | | Directorate Change |
| 20/08/25 | 07:00:13 | 20 Aug 2025 | | HUTCHMED Completes Enrollment of Phase III Trial |
| 07/08/25 | 12:00:01 | 7 Aug 2025 | | 2025 Interim Results |
| 03/07/25 | 09:30:00 | 3 Jul 2025 | | HUTCHMED to Announce 2025 Half-Year Results |
| 02/07/25 | 10:00:00 | 2 Jul 2025 | | Update on Joint Corporate Brokers in London |
| 30/06/25 | 09:30:00 | 30 Jun 2025 | | China Approval based on Phase III SACHI Trial |
| 30/06/25 | 09:30:00 | 30 Jun 2025 | | Total Voting Rights |
| 30/06/25 | 09:30:00 | 30 Jun 2025 | | Blocklisting Six Monthly Return |
| 10/06/25 | 11:00:01 | 10 Jun 2025 | | Grant of Share Options and Awards under LTIP |
| 05/06/25 | 07:00:19 | 5 Jun 2025 | | HUTCHMED and Innovent Announce NDA Acceptance |
| 02/06/25 | 07:00:14 | 2 Jun 2025 | | HUTCHMED Highlights SACHI Phase III Data at ASCO |
| 30/05/25 | 09:30:01 | 30 May 2025 | | Total Voting Rights |
| 23/05/25 | 07:00:09 | 23 May 2025 | | HUTCHMED Highlights Data to be Presented at ASCO |
| 13/05/25 | 11:45:00 | 13 May 2025 | | AGM held on May 13, 2025 – Poll Results |
| 24/04/25 | 07:00:13 | 24 Apr 2025 | | HUTCHMED - Data to be Presented at AACR 2025 |
| 22/04/25 | 07:00:15 | 22 Apr 2025 | | HUTCHMED Completes Enrollment of Phase II Study |
